Heteroplasmy of mutant mitochondrial DNA A10398G and analysis of its prognostic value in non-small cell lung cancer

Qi,Yuexiao; Wei,Yuehua; Wang,Qiaoli; Xu,Hui; Wang,You; Yao,Anqi; Yang,Hui; Gao,Yan; Zhou,Fuxiang

doi:10.3892/ol.2016.5086

Heteroplasmy of mutant mitochondrial DNA A10398G and analysis of its prognostic value in non-small cell lung cancer

Authors:
- Yuexiao Qi
- Yuehua Wei
- Qiaoli Wang
- Hui Xu
- You Wang
- Anqi Yao
- Hui Yang
- Yan Gao
- Fuxiang Zhou
View Affiliations

Affiliations: Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, P.R. China
Published online on: September 5, 2016 https://doi.org/10.3892/ol.2016.5086
Pages: 3081-3088
Copyright: © Qi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Mitochondrial dysfunction is associated with pathogenic mitochondrial (mt)DNA mutations. The majority of mtDNA point mutations have a heteroplasmic status, which is defined as the coexistence of wild‑type and mutated DNA within a cell or tissue. Previous findings demonstrated that certain mtDNA heteroplasmic mutations contribute to widely spread chronic diseases, including cancer, and alterations in the heteroplasmy level are associated with the clinical phenotype and severity of cancer. In the present study, the proportions of mutant mtDNA 10398G were assessed using amplification‑refractory mutation system‑quantitative polymerase chain reaction (PCR) assay in 129 non‑small cell lung cancer (NSCLC) tissue samples. Wild‑type and mutant sequences were separately amplified using allele‑specific primers and, subsequently, the PCR products containing the mtDNA 10398 site were ligated into vectors to construct a standard plasmid DNA construct. The association between mtDNA A10398G and the prognosis of patients was analyzed by survival analysis and Cox proportional hazards model. For the patient cohort, the median follow‑up time and overall survival time were 20.6 and 26.3 months, respectively. The ratios of mutant heteroplasmy ranged between 0.31 and 97.04%. Patients with a high degree of mutant mtDNA 10398G had a significantly longer overall survival time compared with those with a low degree of mutant mtDNA 10398G (28.7 vs. 22.5 months, respectively; P<0.05). In addition, multivariate analysis demonstrated that epidermal growth factor receptor mutation status, tumor stage and the possession of a low degree of mutant 10398G were the three most independent prognostic factors. In conclusion, the present study suggests that, among NSCLC patients, there are large shifts in mutant mtDNA 10398G heteroplasmy and a low degree of mutant mtDNA 10398G heteroplasmy may be a marker of poor prognosis in patients with NSCLC.

View Figures

View References

1	Wallace DC, Fan W and Procaccio V: Mitochondrial energetics and therapeutics. Annu Rev Pathol. 5:297–348. 2010. View Article : Google Scholar : PubMed/NCBI
2	Sanchez-Aragó M, Chamorro M and Cuezva JM: Selection of cancer cells with repressed mitochondria triggers colon cancer progression. Carcinogenesis. 31:567–576. 2010. View Article : Google Scholar : PubMed/NCBI
3	Johns DR: Seminars in medicine of the Beth Israel Hospital, Boston. Mitochondrial DNA and disease. N Engl J Med. 333:638–644. 1995.PubMed/NCBI
4	Schon EA: Mitochondrial genetics and disease. Trends Biochem Sci. 25:555–560. 2000. View Article : Google Scholar : PubMed/NCBI
5	Bai RK and Wong LJ: Detection and quantification of heteroplasmic mutant mitochondrial DNA by real-time amplification refractory mutation system quantitative PCR analysis: A single-step approach. Clin Chem. 50:996–1001. 2004. View Article : Google Scholar : PubMed/NCBI
6	Larsen NB, Rasmussen M and Rasmussen LJ: Nuclear and mitochondrial DNA repair: Similar pathways? Mitochondrion. 5:89–108. 2005. View Article : Google Scholar : PubMed/NCBI
7	Rozwodowska M, Drewa G, Zbytniewski Z, Woźniak A, Krzyzyńska-Malinowska E and Maciak R: Mitochondrial diseases. Med Sci Monit. 6:817–822. 2000.PubMed/NCBI
8	Wallace DC: The mitochondrial genome in human adaptive radiation and disease: On the road to therapeutics and performance enhancement. Gene. 354:169–180. 2005. View Article : Google Scholar : PubMed/NCBI
9	Wallace DC: Mitochondrial DNA mutations in disease and aging. Environ Mol Mutagen. 51:440–450. 2010.PubMed/NCBI
10	Lin CS, Wang LS, Tsai CM and Wei YH: Low copy number and low oxidative damage of mitochondrial DNA are associated with tumor progression in lung cancer tissues after neoadjuvant chemotherapy. Interact Cardiovasc Thorac Surg. 7:954–958. 2008. View Article : Google Scholar : PubMed/NCBI
11	Choi SJ, Kim SH, Kang HY, Lee J, Bhak JH, Sohn I, Jung SH, Choi YS, Kim HK, Han J, et al: Mutational hotspots in the mitochondrial genome of lung cancer. Biochem Biophys Res Commun. 407:23–27. 2011. View Article : Google Scholar : PubMed/NCBI
12	Pezzotti A, Kraft P, Hankinson SE, Hunter DJ, Buring J and Cox DG: The mitochondrial A10398G polymorphism, interaction with alcohol consumption and breast cancer risk. PLoS One. 4:e53562009. View Article : Google Scholar : PubMed/NCBI
13	Jin X, Zhang J, Gao Y, Ding K, Wang N, Zhou D, Jen J and Cheng S: Relationship between mitochondrial DNA mutations and clinical characteristics in human lung cancer. Mitochondrion. 7:347–353. 2007. View Article : Google Scholar : PubMed/NCBI
14	Zu-Jian C, Bin Y, Qi-Cai L, Lin J, Jing C and Qi-Shui O: Quantification of mitochondrial DNA with the A1555G mutation in deaf patients using real-time amplification refractory mutation system-quantitative PCR. J Mol Diagn. Dec 3–2009.(Epub ahead of print). PubMed/NCBI
15	Newton CR, Graham A, Heptinstall LE, Powell SJ, Summers C, Kalsheker N, Smith JC and Markham AF: Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Res. 17:2503–2516. 1989. View Article : Google Scholar : PubMed/NCBI
16	Beasley MB, Brambilla E and Travis WD: The 2004 World Health Organization classification of lung tumors. Semin Roentgenol. 40:90–97. 2005. View Article : Google Scholar : PubMed/NCBI
17	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
18	Venegas V and Halberg MC: Quantification of mtDNA mutation heteroplasmy (ARMS qPCR). Methods Mol Biol. 837:313–326. 2012. View Article : Google Scholar : PubMed/NCBI
19	Kulawiec M, Owens KM and Singh KK: mtDNA G10398A variant in African-American women with breast cancer provides resistance to apoptosis and promotes metastasis in mice. J Hum Genet. 54:647–654. 2009. View Article : Google Scholar : PubMed/NCBI
20	Canter JA, Kallianpur AR, Parl FF and Millikan RC: Mitochondrial DNA G10398A polymorphism and invasive breast cancer in African-American women. Cancer Res. 65:8028–8033. 2005.PubMed/NCBI
21	Lee HC, Chang CM and Chi CW: Somatic mutations of mitochondrial DNA in aging and cancer progression. Ageing Res Rev. 9(Suppl 1): S47–S58. 2010. View Article : Google Scholar : PubMed/NCBI
22	Xu H, He W, Jiang HG, Zhao H, Peng XH, Wei YH, Wei JN, Xie CH, Liang C, Zhong YH, et al: Prognostic value of mitochondrial DNA content and G10398A polymorphism in non-small cell lung cancer. Oncol Rep. 30:3006–3012. 2013.PubMed/NCBI
23	Wong LJ and Bai RK: Real-time quantitative polymerase chain reaction analysis of mitochondrial DNA point mutation. Methods Mol Biol. 335:187–200. 2006.PubMed/NCBI
24	Zhu Y, Huang S, Kang D, Han M, Wang G, Yuan Y, Su Y, Yuan H, Zhai S and Dai P: Analysis of the heteroplasmy level and transmitted features in hearing-loss pedigrees with mitochondrial 12S rRNA A1555G mutation. BMC Genet. 15:262014. View Article : Google Scholar : PubMed/NCBI
25	Warowicka A, Kwasniewska A and Gozdzicka-Jozefiak A: Alterations in mtDNA: A qualitative and quantitative study associated with cervical cancer development. Gynecol Oncol. 129:193–198. 2013. View Article : Google Scholar : PubMed/NCBI
26	Sobenin IA, Mitrofanov KY, Zhelankin AV, Sazonova MA, Postnov AY, Revin VV, Bobryshev YV and Orekhov AN: Quantitative assessment of heteroplasmy of mitochondrial genome: Perspectives in diagnostics and methodological pitfalls. Biomed Res Int. 2014:2920172014. View Article : Google Scholar : PubMed/NCBI